Panacea Biotec's Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- Panacea Biotec Ltd reported a 13.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 0.2%.
- Its expenses for the quarter were down by 3.3% QoQ and 1.1% YoY.
- The net profit decreased 127.8% QoQ and decreased 12.4% YoY.
- The earnings per share (EPS) of Panacea Biotec Ltd stood at 0.65 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 167.47 | 147.53 | 167.11 | 13.5% | 0.2% |
Total Expenses | 163.75 | 169.40 | 165.50 | -3.3% | -1.1% |
Profit Before Tax | 6.49 | -19.17 | 4.38 | -133.9% | 48.2% |
Tax | 2.60 | -5.16 | -0.06 | -150.4% | -4433.3% |
Profit After Tax | 3.89 | -14.01 | 4.44 | -127.8% | -12.4% |
Earnings Per Share | 0.65 | -2.27 | 0.74 | -128.6% | -12.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Panacea Biotec Ltd is a pharmaceutical and biotechnology company based in India. It is primarily engaged in the research, development, production, and marketing of pharmaceutical formulations and vaccines. The company operates within the highly competitive biopharmaceutical industry, focusing on creating innovative healthcare solutions. Specific major recent developments within the company are not available in the data. Panacea Biotec has historically been involved in partnerships and collaborations to advance its product portfolio, though specifics of such activities in the recent quarter are not provided.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Panacea Biotec Ltd reported total income of ₹167.47 crores. This reflects a quarter-over-quarter (QoQ) increase of 13.5% compared to ₹147.53 crores in Q2FY26 and a year-over-year (YoY) increase of 0.2% compared to ₹167.11 crores in Q3FY25. The revenue figures demonstrate a positive trend in the company's income over the recent quarter, with a slight increase when compared to the same quarter in the previous year.
Profitability
For Q3FY26, Panacea Biotec Ltd recorded a profit before tax (PBT) of ₹6.49 crores, a significant improvement from a loss of ₹19.17 crores in the previous quarter (Q2FY26). This represents a QoQ change of -133.9%. Compared to Q3FY25, where the PBT was ₹4.38 crores, there is a YoY increase of 48.2%. The profit after tax (PAT) for Q3FY26 was ₹3.89 crores, contrasting with a loss of ₹14.01 crores in Q2FY26, and showing a YoY decrease of 12.4% from ₹4.44 crores in Q3FY25. The earnings per share (EPS) for this quarter was ₹0.65, up from a loss of ₹2.27 in Q2FY26, but down 12.2% YoY from ₹0.74 in Q3FY25.
Operating Metrics
The total expenses incurred by Panacea Biotec Ltd in Q3FY26 were ₹163.75 crores, which is a decrease of 3.3% compared to the previous quarter (Q2FY26) where expenses were ₹169.40 crores. Year-over-year, total expenses decreased by 1.1% from ₹165.50 crores in Q3FY25. The decrease in expenses over both the quarter and the year can be noted. Tax expenses for Q3FY26 were ₹2.60 crores, a significant increase from a negative tax expense of ₹-5.16 crores in Q2FY26, and up from a negative tax expense of ₹-0.06 crores in Q3FY25, reflecting a YoY change of -4433.3%. These metrics indicate variations in the company’s cost and tax structure over the periods but do not provide additional context on underlying reasons.